Details of the Drug Combination

General Information of Drug Combination (ID: DC9F5L7)

• Drug Combination Name: Endoxifen + Phensuximide
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  Endoxifen (DMTX8IZ): Small molecular drug
  Phensuximide (DMFGLXB): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 34.28
  Bliss Independence Score: 34.28
  Loewe Additivity Score: 50.18
  LHighest Single Agent (HSA) Score: 50.22

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Endoxifen

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Phase 2	[2]

Endoxifen Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Estrogen receptor (ESR)	TTZAYWL	ESR1_HUMAN	Modulator	[5]

Indication(s) of Phensuximide

Disease Entry	ICD 11	Status	REF
Absence epilepsy	N.A.	Approved	[3]
Epilepsy	8A60-8A68	Approved	[3]
Seizure disorder	8A6Z	Approved	[4]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] ClinicalTrials.gov (NCT02311933) Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer. U.S.National Institutes of Health.
• [3] Phensuximide FDA Label
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7612).
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).